Payment overview · 2025
General Payments
$491.38
20 reported records · 8 companies
Healthcare provider profile · identity verified
Richard E Hodgman, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · KALKASKA, MI · NPI 1275561474
Verified facts
What the public records show
CMS Open Payments records show Richard E Hodgman, M.D. received $491.38 in general payments during 2025 across 20 reported records.
Janssen Pharmaceuticals, Inc accounted for 37.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $181.58 | 37.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $173.80 | 35.4% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.89 | 6.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.26 | 4.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $22.99 | 4.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.44 | 4.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.84 | 3.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.58 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $491.38 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $181.58 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.77 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $87.14 | 5 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $1.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 187 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 162 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 162 | 26 |
| Lisinopril | Lisinopril | 155 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 131 | 44 |
| Omeprazole | Omeprazole | 122 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 47 |
| Morphine Sulfate Er | Morphine Sulfate | 100 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 30 |
| Gabapentin | Gabapentin | 84 | 29 |
| Metformin Hcl | Metformin Hcl | 78 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 22 |
| Prednisone | Prednisone | 76 | 43 |
| Tramadol Hcl | Tramadol Hcl | 67 | 15 |
| Clonazepam | Clonazepam | 62 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 17 |
| Jardiance | Empagliflozin | 61 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 61 | 22 |
| Potassium Chloride | Potassium Chloride | 61 | 18 |
| Methadone Hcl | Methadone Hcl | 59 | suppressed |
| Eliquis | Apixaban | 58 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 23 |
| Losartan Potassium | Losartan Potassium | 55 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 18 |
| Furosemide | Furosemide | 53 | 19 |
| Trazodone Hcl | Trazodone Hcl | 51 | 16 |
| Carvedilol | Carvedilol | 47 | 16 |
| Pregabalin | Pregabalin | 45 | suppressed |
| Aripiprazole | Aripiprazole | 44 | 12 |
| Spironolactone | Spironolactone | 43 | 11 |
| Alprazolam | Alprazolam | 42 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 18 |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Simvastatin | Simvastatin | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 29 | 11 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 13 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 11 |
| Celecoxib | Celecoxib | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $491.38 · 20 records | Janssen Pharmaceuticals, Inc | AUSTEDO XR, Cologuard Collection Kit, ESPRIT, JARDIANCE, MOUNJARO, NURTEC ODT, QULIPTA, SPRAVATO, UBRELVY, VRAYLAR, WaveWriter Alpha Prime 16, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error